Dr. Byrd on Alacabrutinib's Mechanism of Action in CLL

Video

John Byrd, MD, director of the Division of Hematology, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Ohio State University Comprehensive Cancer Center, discusses the mechanism of acalabrutinib, a next-generation BTK inhibitor as a potential treatment for patients with chronic lymphocytic leukemia.

John Byrd, MD, director of the Division of Hematology, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Ohio State University Comprehensive Cancer Center, discusses the mechanism of acalabrutinib, a next-generation, selective BTK inhibitor as a potential treatment for patients with chronic lymphocytic leukemia (CLL).

Acalabrutinib has the ideal properties of an irreversible inhibitor, Byrd explains, as well as has a short half-life. Additionally, it is selective for BTK and only affects two other kinases. Because of this, there can be more direct targeting on BTK.

There can also be a higher frequency of dosing, which could provide an opportunity to treat fast-growing tumors, Byrd adds.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD